2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart …
JA Joglar, MK Chung, AL Armbruster, EJ Benjamin… - Circulation, 2024 - Am Heart Assoc
AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial
Fibrillation” provides recommendations to guide clinicians in the treatment of patients with …
Fibrillation” provides recommendations to guide clinicians in the treatment of patients with …
Evaluation and treatment of amiodarone-induced thyroid disorders
Amiodarone is a class III antiarrhythmic drug containing 37% iodine by weight, with a
structure similar to that of thyroid hormones. Deiodination of amiodarone releases large …
structure similar to that of thyroid hormones. Deiodination of amiodarone releases large …
[HTML][HTML] Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system
Y Shu, X He, P Wu, Y Liu, Y Ding, Q Zhang - Frontiers in public health, 2022 - frontiersin.org
Background Semaglutide was approved for treatment of type 2 diabetes mellitus (T2DM)
and chronic weight management in obesity or overweight adults. However, real-world data …
and chronic weight management in obesity or overweight adults. However, real-world data …
[HTML][HTML] Neurological adverse events associated with esketamine: a disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
H Guo, B Wang, S Yuan, S Wu, J Liu, M He… - Frontiers in …, 2022 - frontiersin.org
Esketamine was approved for the treatment of treatment-resistant depression in 2019. After
the approval of esketamine, numerous concerns have been raised regarding its long-term …
the approval of esketamine, numerous concerns have been raised regarding its long-term …
The impact of anti-TNFα agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system …
F Mazhar, V Battini, M Gringeri, M Pozzi… - Expert opinion on …, 2021 - Taylor & Francis
Introduction Studies in patients with immune-mediated inflammatory diseases (IMIDs) have
inconsistently suggested that anti-TNFα therapy may be associated with excessive weight …
inconsistently suggested that anti-TNFα therapy may be associated with excessive weight …
[HTML][HTML] A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
Z Cui, F Cheng, L Wang, F Zou, R Pan, Y Tian… - Frontiers in …, 2023 - frontiersin.org
Introduction: Etoposide is a broad-spectrum antitumor drug that has been extensively
studied in clinical trials. However, limited information is available regarding its real-world …
studied in clinical trials. However, limited information is available regarding its real-world …
[HTML][HTML] Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database
F Zou, Z Cui, S Lou, Y Ou, C Zhu, C Shu… - Frontiers in …, 2024 - frontiersin.org
Introduction: Linezolid is an oxazolidinone antibiotic that is active against drug-resistant
Gram-positive bacteria and multidrug-resistant Mycobacterium tuberculosis. Real-world …
Gram-positive bacteria and multidrug-resistant Mycobacterium tuberculosis. Real-world …
[HTML][HTML] A real-world disproportionality analysis of rucaparib: post-marketing pharmacovigilance data
Q Zhang, Y Ding, Y Shu, J Chen - BMC cancer, 2023 - Springer
Background Rucaparib has been approved for the maintenance treatment of adult patients
with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. However, the …
with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. However, the …
Amiodarone-induced thyrotoxicosis
L Schubert, L Bricaire, L Groussin - Annales d'Endocrinologie, 2021 - Elsevier
Amiodarone-induced thyrotoxicosis (AIT) are not uncommon endocrinopathies. Clinicians
are sometimes faced with difficult diagnostic and therapeutic situations. The disease …
are sometimes faced with difficult diagnostic and therapeutic situations. The disease …
Post-marketing risk analysis of bendamustine: a real-world approach based on the FAERS database
D Li, Y Zhang, JQ Ni, J Zhu, WT Lu, YL Chen… - Frontiers in …, 2024 - frontiersin.org
Objective: Bendamustine was approved for treating chronic lymphocytic leukemia and
indolent B-cell non-Hodgkin lymphoma. Despite its therapeutic benefits, the long-term safety …
indolent B-cell non-Hodgkin lymphoma. Despite its therapeutic benefits, the long-term safety …